CDNA
CareDx, Inc.stockNASDAQ
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 79.81 | 2026-11-12 | -6.85% | 2.316 |
| 1M | 67.08 | 2026-10-19 | +10.82% | 1.182 |
| 3M | 46.51 | 2026-08-19 | +59.84% | 1.257 |
| 6M | 20.53 | 2026-05-19 | +262.10% | 1.171 |
| 1Y | 15.98 | 2025-11-19 | +365.21% | 1.254 |
| 2Y | 22.06 | 2024-11-19 | +236.99% | — |
| 5Y | 43.01 | 2021-11-19 | +72.84% | 1.539 |
CareDx, Inc. (NASDAQ:CDNA) stock price today is $74.34, and today's volume is 537,509. CDNA is down 0.295% today. The 30 day average volume is 1.26M. CDNA market cap is $3.91B with 52.54M shares outstanding.